Table 2.

Use of Trastuzumb Among Women With HER2-Positive Breast Cancer

Characteristic	Total No. of Women	Women Receiving Trastuzumab		P	Odds Ratio	95% CI
		No.	%
Age, years	137	79	57.7	.44	1.05	0.71 to 1.56
35-49	47	25	53.2
50-65	90	54	60.0
Menopausal status	137			.33
Premenopausal	48	25	52.1		Ref
Postmenopausal	89	54	60.7		1.45	0.46 to 4.59
Income	131			.02
< $40,000	34	27	79.4		4.43	1.22 to 16.04
$40,000-$74,999	47	22	46.8		1.01	0.34 to 3.00
$75,000-$124,999	27	16	59.3		1.61	0.47 to 5.51
≥ $125,000	23	11	47.8		Ref
Health plan type	137			.09
Health maintenance organization	49	33	67.4		1.60	0.64 to 3.98
Other plan type*	88	46	52.3		Ref
Comorbidity score	137			.68
0	114	66	57.9		Ref
1	16	10	62.5		1.02	0.27 to 3.80
≥ 2	7	3	42.9		0.79	0.16 to 3.83
Cancer stage	137			.03
I	66	31	47.0		Ref
II	52	37	71.2		1.91	0.78 to 4.70
III	19	11	57.9		1.39	0.43 to 4.54
Estrogen receptor status	136			.23
Positive	95	52	54.7		Ref
Negative	41	27	65.9		1.49	0.65 to 3.40
Breast cancer surgery	137			.50
Lumpectomy	71	39	54.9		Ref
Mastectomy	66	40	60.6		1.38	0.59 to 3.21
Census region	137			.32
Northeast	42	25	59.5		0.99	0.43 to 2.32
Midwest	12	4	33.3		0.30	0.07 to 1.24
South	68	40	58.8		Ref
West	15	10	66.7		1.82	0.46 to 7.16

^*Includes point of service, indemnity, and preferred provider organization plans.